Efficacy of grass pollen allergen sublingual immunotherapy tablets for seasonal allergic rhinoconjunctivitis: A systematic review and meta-analysis

JAMA Internal Medicine

Volumn 175, Issue 8, 2015, Pages 1301-1309

  Di Bona, Danilo ^a   Plaia, Antonella ^b   Leto Barone, Maria Stefania ^b   La Piana, Simona ^b   Di Lorenzo, Gabriele ^a,b  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; GRASS POLLEN EXTRACT; PLACEBO; ALLERGEN; PLANT ANTIGEN; PLANT EXTRACT; SWEET VERNAL, ORCHARD, PERENNIAL RYE, TIMOTHY AND KENTUCKY BLUE GRASS MIXED POLLENS ALLERGEN EXTRACT;

ANAPHYLAXIS; ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; META ANALYSIS; PHLEUM PRATENSE; POLLEN ALLERGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; STANDARDIZED MEAN DIFFERENCE; STATISTICAL ANALYSIS; SUBLINGUAL IMMUNOTHERAPY; SYSTEMATIC REVIEW; TABLET; UNSPECIFIED SIDE EFFECT; CONJUNCTIVITIS, ALLERGIC; PROCEDURES; RHINITIS, ALLERGIC, SEASONAL;

ALLERGENS; ANTIGENS, PLANT; CONJUNCTIVITIS, ALLERGIC; HUMANS; PLANT EXTRACTS; RHINITIS, ALLERGIC, SEASONAL; SUBLINGUAL IMMUNOTHERAPY;

EID: 84939825158     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2015.2840     Document Type: Article

References (51)

1. Bernstein JA. Characterizing rhinitis subtypes. Am J Rhinol Allergy. 2013;27(6):457-460.
2. Greiner AN, Hellings PW, Rotiroti G, Scadding GK. Allergic rhinitis. Lancet. 2011;378(9809): 2112-2122.
3. Portnoy JM, Sampson H. Management of allergic rhinitis. Lancet.2008;372(9643):1037.
4. Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Di Lorenzo G. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison. J Allergy Clin Immunol. 2012;130(5): 1097-1107.e2. doi:10.1016/j.jaci.2012.08.012.
5. Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7(1):6.
6. US Food and Drug Administration. Approval notification of Oralair. Approved in 2014. http://www.fda.gov/downloads/BiologicsBloodVaccines/Allergenics/UCM391580.pdf. Accessed April 4, 2014.
7. US Food and Drug Administration. April 11, 2014 approval letter: Grastek. http://www.fda.gov/biologicsbloodvaccines/allergenics/ucm393185.htm. Accessed April 15, 2014.
8. Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006;117(5):1021-1035.
9. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999;341(7):468-475.
10. Cox L, Wallace D. Specific allergy immunotherapy for allergic rhinitis: subcutaneous and sublingual. Immunol Allergy Clin North Am. 2011;31(3):561-599.
11. Calderón MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol. 2011;127(1):30-38.
12. Di Bona D, Plaia A, Scafidi V, Leto-Barone MS, Di Lorenzo G. Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. J Allergy Clin Immunol. 2010;126(3):558-566.
13. Pradalier A, Basset D, Claudel A, et al. Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy. 1999;54(8):819-828.
14. Caffarelli C, Sensi LG, Marcucci F, Cavagni G. Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial. Allergy. 2000;55(12):1142-1147.
15. Smith H, White P, Annila I, Poole J, Andre C, Frew A. Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis. J Allergy Clin Immunol.2004;114(4): 831-837.
16. Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006; 118(2):434-440.
17. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.Allergy. 2006;61(2):185-190.
18. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006; 117(4):802-809.
19. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;120(6):1338-1345.
20. Horak F, Zieglmayer P, Zieglmayer R, et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol. 2009;124(3):471-477, 477.e1. doi: 10.1016/j.jaci.2009.06.006.
21. Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol. 2009;123 (1):167-173.e7. doi:10.1016/j.jaci.2008.10.044.
22. Wahn U, Tabar A, Kuna P, et al SLIT Study Group. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2009;123(1):160-166.e3. doi: 10.1016/j.jaci.2008.10.009.
23. Halken S, Agertoft L, Seidenberg J, et al. Five-grass pollen 300IR SLIT tablets: efficacy and safety in children and adolescents. Pediatr Allergy Immunol. 2010;21(6):970-976.
24. Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents [published correction appears in J Allergy Clin Immunol. 2011;128(2):436]. J Allergy Clin Immunol. 2011;127(1):64-71, 71.e1-71.e4. doi:10.1016/j.jaci.2010.11.034.
25. Nelson HS, Nolte H, Creticos P, Maloney J, Wu J, Bernstein DI. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol. 2011;127(1):72-80, 80.e1-80.e2. doi: 10.1016/j.jaci.2010.11.034.
26. Cox LS, Casale TB, Nayak AS, et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. J Allergy Clin Immunol. 2012;130(6): 1327-1334.e1. doi:10.1016/j.jaci.2012.08.032.
27. Murphy K, Gawchik S, Bernstein D, Andersen J, Pedersen MR. A phase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen-induced allergic rhinitis with or without conjunctivitis, with or without asthma.JNegat Results Biomed. 2013;12:10-19.
28. Maloney J, Bernstein DI, Nelson H, et al. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol. 2014;112(2):146-153.e2. doi:10.1016/j.anai.2013.11.018.
29. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Updated March 2011. http://handbook.cochrane.org/. Accessed May 20, 2015.
30. Jüni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis.JAMA. 1999;282(11):1054-1060.
31. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12.
32. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials.1986;7(3):177-188.
33. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
34. R Foundation. The R Project for statistical computing. http://www.R-project.org. Accessed May 17, 2015.
35. Schwarzer G. meta: Meta-Analysis With R. R package version 1.1-8. 2010. http://cran.r-project.org/web/packages/meta/index.html. Accessed May 28, 2015.
36. Viechtbauer W. Metafor: Meta-Analysis Package for R. R package version 2010. http://cran.r-project.org/web/packages/metafor/index.html. Accessed May 28, 2015.
37. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-1558.
38. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634.
39. Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: World Allergy Organization position paper 2009. World Allergy Organ J. 2009;2(11):233-281.
40. Canonica GW, Baena-Cagnani CE, Bousquet J, et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy: a statement of a World Allergy Organization (WAO) taskforce. Allergy. 2007;62(3):317-324.
41. Benninger M, Farrar JR, Blaiss M, et al. Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class. Ann Allergy Asthma Immunol. 2010;104(1):13-29.
42. Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med. 2004;116(5):338-344.
43. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2012;12: MR000033.
44. Drugs and devices look more effective in studies sponsored by industry. BMJ. 2012;345:e8386. doi:10.1136/bmj.e8386.
45. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010;(12):CD002893.
46. Dretzke J, Meadows A, Novielli N, Huissoon A, Fry-Smith A, Meads C. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison. J Allergy Clin Immunol. 2013;131(5):1361-1366.
47. Lin SY, Erekosima N, Kim JM, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA. 2013;309(12):1278-1288.
48. Antico A, Fante R. Esophageal hypereosinophilia induced by grass sublingual immunotherapy. J Allergy Clin Immunol. 2014;133 (5):1482-1484.
49. Bernstein DI, Wanner M, Borish L, Liss GM; Immunotherapy Committee, American Academy of Allergy, Asthma and Immunology. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol. 2004;113(6):1129-1136.
50. Di Lorenzo G, Mansueto P, Pacor ML, et al. Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy. J Allergy Clin Immunol. 2009;123(5):1103-1110, 1110.e1-1110.e4. doi:10.1016/j.jaci.2009.02.012.
51. Cromwell O, Häfner D, Nandy A. Recombinant allergens for specific immunotherapy. J Allergy Clin Immunol. 2011;127(4):865-872.